RxDoctor Payments Data

Peter Bressler, MD

Allergy & Immunology · Durham, NCNPI 1972583656

Payments from drug & device makers

$4,452in general payments, 2019–2025

Across 18 payments — averaging $247.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pharming Healthcare, Inc.$3K
  • Astrazeneca UK Limited$1K
  • GSK$65
  • Genentech USA, Inc.$36
  • Sanofi-aventis U.S. LLC$20
  • Tandem Diabetes Care, Inc.$14

What the payments were for

  • Speaking & faculty fees$3,00067%
  • Travel & lodging$95321%
  • Food & beverage$43510%
  • Education$651%

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,452 in reported general payments places this provider in the 45th percentile of 140 allergy & immunology providers in North Carolina.

See all allergy & immunology providers in North Carolina

Medicare billing

Part B allowed, 2024
$66,336
Medicare patients
331
Services billed
2,283

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TakhzyroLanadelumab-Flyo13$675,454
BerinertC1 Esterase Inhibitor12$289,158
NucalaMepolizumab15$140,162
XolairOmalizumab36$115,080
Trelegy ElliptaFluticasone/Umeclidin/Vilanter132$104,168
Breo ElliptaFluticasone/Vilanterol155$87,175
Dupixent PenDupilumab18$67,392
Dupixent SyringeDupilumab14$52,180
Arnuity ElliptaFluticasone Furoate131$33,516
Advair HfaFluticasone Propion/Salmeterol67$31,878
Spiriva RespimatTiotropium Bromide26$16,443
Epinephrine83$15,384
Qvar RedihalerBeclomethasone Dipropionate12$7,576
Azelastine Hcl184$7,548
Incruse ElliptaUmeclidinium Bromide11$7,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKNucala, Trelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta$65$372,444444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 140 allergy & immunology providers in North Carolina.

Other allergy & immunology in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →